Discussion {#onco13072-sec-0006}
==========

Bicalutamide, an AR inhibitor, has shown some promising efficacy and little toxicity in patients with triple‐negative breast cancer; however, data for bicalutamide in patients with ER‐positive, HER2‐negative breast cancer resistant to AI are limited.

In this phase II, Simon\'s two‐stage, single‐arm study, we aimed to evaluate the efficacy and tolerability of bicalutamide plus another AI in patients with AI‐resistant breast cancer. The Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Figure [1](#onco13072-fig-0001){ref-type="fig"}. To our knowledge, this is the first study to investigate the value of bicalutamide in overcoming AI resistance; however, the primary outcome did not meet the preplanned result, leading to termination of the study after the first stage.

![CONSORT flow diagram.\
Abbreviations: CBR, clinical benefit rate; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival.](ONCO-25-21-g001){#onco13072-fig-0001}

Of the 18 patients who were analyzed, only 3 had stable disease at 6 months, and there were no partial or complete responses. The median PFS was 2.7 months (95% confidence interval, 2.2--3.8 months), which was similar to previously reported data. The treatment was well tolerated. The most commonly reported adverse event was pain at any site (3/19 patients). The results did not suggest that large‐sample clinical trials of bicalutamide plus another AI should be conducted to overcome AI resistance in ER‐positive, AR‐positive breast cancer.

Trial Information {#onco13072-sec-0007}
=================

**Disease**Breast cancer**Disease**Advanced cancer/solid tumor only**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**No designated number of regimens**Type of Study -- 1**Phase II**Type of Study -- 2**Single arm**Primary Endpoint**Clinical benefit rate**Secondary Endpoint**Overall response rate**Secondary Endpoint**Progression‐free survival**Secondary Endpoint**Tolerability**Additional Details of Endpoints or Study Design** This study was planned to enroll a total of 58 patients and designed as a single‐arm, two‐stage trial. We assumed the clinical benefit rate would be 40% with type I error of 0.1 and type II error of 0.2. If fewer than four patients benefited from the treatment in the first stage, the trial would be terminated. On the contrary, if at least four patients benefited from the treatment in the first stage, the trial would continue recruiting patients. Patients meeting all eligibility requirements would receive bicalutamide 50 mg daily and aromatase inhibitor according to instructions in continuous 28‐day cycles. Patients would receive another type of aromatase inhibitor if resistance to one type of aromatase inhibitor had been observed. Both premenopausal and postmenopausal women could participate in the trial, and premenopausal women should use luteinizing hormone releasing hormone analog continuously. The primary outcome was CBR; the secondary outcomes were PFS, ORR, and tolerability. CBR was defined as the ratio of patients who had response or stable disease according to RECIST version 1.1 definitions for over 24 weeks. ORR was defined as the ratio of patients with complete response or partial response according to RECIST 1.1. PFS was defined as time from treatment to disease progression or death. Clinical assessment would be done every 2 months for the first half year, then every 3 months until disease progression, unacceptable adverse events due to treatment, or death. Patients would then be followed until 2 years after the last enrolled patient, death, consent withdrawal, or loss of follow‐up. This study was approved by the ethics review board of our center, and written inform consent was obtained from all patients. **Investigator\'s Analysis**Level of activity did not meet planned endpoint.

Drug Information {#onco13072-sec-0008}
================

Drug 1   **Generic/Working Name**Bicalutamide  **Trade Name**Casodex  **Company Name**AstraZeneca  **Drug Type**Small molecule  **Drug Class**Androgen receptor  **Dose**50 milligrams (mg) per flat dose  **Route**Oral (p.o.)  **Schedule of Administration**50 mg daily continuouslyDrug 2   **Generic/Working Name**Letrozole or Anastrozole or Exemestane  **Trade Name**Femera or Arimidex or Aromasin  **Company Name**Novartis or AstraZeneca or Pfizer  **Drug Type**Small molecule  **Drug Class**Estrogen receptor  **Dose**2.5 or 1 or 25 milligrams (mg) per flat dose  **Route**Oral (p.o.)  **Schedule of Administration**Letrozole: 2.5 mg orally continuouslyAnastrozole: 1 mg orally continuouslyExemestane: 25 mg orally continuously

Dose Escalation Table for Phase I Experimental {#onco13072-sec-1008}
==============================================

Dose levelDose of drug: bicalutamideDose of drug: letrozole, anastrozole, or exemestaneNumber enrolledNumber evaluable for toxicityInitial dose50 mg2.5 mg, 1 mg, 25 mg1919John Wiley & Sons, Ltd.

Patient Characteristics {#onco13072-sec-0009}
=======================

Number of Patients, Male0Number of Patients, Female18StageStage IVAgeMedian (range): 48 (32--70) yearsNumber of Prior Systemic TherapiesMedian (range): 1 (0--4)Performance Status: Eastern Cooperative Oncology Group0 --- 81 --- 82 --- 23 --- 0Unknown --- 0

Detailed Patient Characteristics {#onco13072-sec-1009}
================================

Characteristic*n*Visceral metastasis Yes15No3No. of metastatic organs 1427≥37Androgen receptor expression \>50%1010%--50%8Progesterone receptor expression 0%--10%15\>10%3Estrogen receptor expression \>50%151%--50%3DFI De novo stage IV2DFI \<24 m360 m \> DFI ≥ 24 m7DFI ≥60 m6Prior ET for primary disease SERM11Nonsteroidal aromatase inhibitor3Steroidal aromatase inhibitor2Prior estrogen therapy for metastatic disease Progression during adjuvant ET4Selective estrogen receptor modulator1Steroidal AI3Nonsteroidal AI10CT for metastatic disease Yes10No8Abbreviations: AI, aromatase inhibitor; CT, chemotherapy; DFI, disease‐free interval; ET, endocrine therapy; SERM, selective estrogen receptor modulator. 

Primary Assessment Method {#onco13072-sec-0010}
=========================

TitleNew AssessmentNumber of Patients Screened19Number of Patients Enrolled19Number of Patients Evaluable for Toxicity19Number of Patients Evaluated for Efficacy18Evaluation MethodRECIST 1.1Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 0 (0%)Response Assessment SD*n* = 3 (16.7%)Response Assessment PD*n* = 15 (83.3%)Response Assessment OTHER*n* = 0 (0%)(Median) Duration Assessments PFS2.7 months; 95% confidence interval, 2.2--3.8 months

Kaplan‐Meier Time Units {#onco13072-sec-2010}
=======================

Time of scheduled assessment and/or time of event, monthsNo. progressed (or deaths)No. censoredPercent at start of evaluation periodKaplan‐Meier %No. at next evaluation/No. at risk000100.00100.0018120100.0088.891622088.8977.781435077.7850.00944050.0027.78550027.7827.78562027.7816.67371016.6711.11280011.1111.11292011.110.000John Wiley & Sons, Ltd.

![Progression‐free survival of all patients.](ONCO-25-21-g002){#onco13072-fig-0002}

Adverse Events {#onco13072-sec-2015}
==============

All CyclesNameNC/NA, %Grade 1, %Grade 2, %Grade 3, %Grade 4, %Grade 5, %All grades, %Tumor pain8317000017Alopecia94600006Hot flashes94600006Peripheral sensory neuropathy94600006Insomnia94600006Hypertension94060006John Wiley & Sons, Ltd.[^2][^3]

Dose‐Limiting Toxicities {#onco13072-sec-2016}
========================

Dose levelNumber enrolledNumber evaluable for toxicityNumber with a dose‐limiting toxicityDose‐limiting toxicity information50 mg191900John Wiley & Sons, Ltd.

Assessment, Analysis, and Discussion {#onco13072-sec-0011}
====================================

CompletionStudy completedTerminated ReasonDid not fully accrueInvestigator\'s AssessmentLevel of activity did not meet planned endpoint.

 {#onco13072-sec-1011}

Endocrine therapy is the mainstay of treatment and significantly improves overall survival in patients with estrogen receptor (ER)‐positive advanced breast cancer. Aromatase inhibitors (AIs), including the nonsteroidal AIs (NSAI), letrozole and anastrozole, and the steroidal AI, exemestane, are widely used in first line treatment. However, resistance is the major obstacle in clinical practice [1](#onco13072-bib-0001){ref-type="ref"}. Overcoming drug resistance is essential in endocrine therapy.

One of the potential mechanisms may be activation of androgen receptor (AR) signaling. AR is widely expressed in breast cancer cells. More than 70% of breast cancer is AR positive, and AR positivity is conserved during tumor progression [2](#onco13072-bib-0002){ref-type="ref"}, [3](#onco13072-bib-0003){ref-type="ref"}. Studies showed that AR positivity was associated with good prognosis regardless of subtype [4](#onco13072-bib-0004){ref-type="ref"}, [5](#onco13072-bib-0005){ref-type="ref"}. Studies have shown that cancer cells that are resistant to AI could convert to AR dependence rather than ER dependence, leading to activation of the EGFR pathway and then promotion of cell growth [6](#onco13072-bib-0006){ref-type="ref"}. Furthermore, AR can promote proliferation of breast cancer cells, epithelial‐mesenchymal transition, and metastasis through activation of the JAK/STAT3, MAPK, NOTCH, and PI3K/AKT/mTOR pathways [7](#onco13072-bib-0007){ref-type="ref"}, [8](#onco13072-bib-0008){ref-type="ref"}. Preclinical studies showed that AR inhibitors could significantly inhibit cell proliferation and promote cell apoptosis in both triple‐negative breast cancer and AI‐resistant cell lines [9](#onco13072-bib-0009){ref-type="ref"}, [10](#onco13072-bib-0010){ref-type="ref"}, [11](#onco13072-bib-0011){ref-type="ref"} AR may be not only a prognostic factor but also a new treatment target in breast cancer.

AR‐targeted therapy has shown some promising preliminary results [12](#onco13072-bib-0012){ref-type="ref"}. Bicalutamide, a nonsteroidal AR antagonist, interrupts the DNA‐binding domain binding to androgen‐related elements [13](#onco13072-bib-0013){ref-type="ref"}. A phase II study showed that bicalutamide achieved 19% of clinical benefit rate (CBR) at 6 months and 12 weeks of median progression‐free survival (PFS) in patients with ER‐negative, AR‐positive advanced breast cancer [14](#onco13072-bib-0014){ref-type="ref"}. Other AR inhibitors and CYP17A inhibitors showed a CBR at 6 months of 7% to 29% in monotherapy or in combination with endocrine therapy in breast cancer and good safety in both monotherapy and combination [15](#onco13072-bib-0015){ref-type="ref"}, [16](#onco13072-bib-0016){ref-type="ref"}, [17](#onco13072-bib-0017){ref-type="ref"}. The combination of AR antagonist with endocrine therapy may show more efficiency in ER‐positive, AR‐positive breast cancer that has progressed after one type of AI. However, studies of the combination of AI and bicalutamide have not been reported.

The aim of this study was to assess the efficacy and safety of bicalutamide plus another AI in patients with both ER‐ and AR‐positive breast cancer after disease progression following one type of AI.

This study did not meet the primary outcome we planned. No improvement in CBR was observed when adding bicalutamide to a second line of AI in patients whose disease had progressed after a previous AI. As we know, the CBR at 6 months of steroidal AI is about 12%\~20% in patients who experience disease progression after NSAI resistance [17](#onco13072-bib-0017){ref-type="ref"}, [18](#onco13072-bib-0018){ref-type="ref"}. In our study, the CBR at 6 months was 16.7% and the median PFS was 2.7 months, which was consistent with the previously reported results and did not show synergistic effects in combination bicalutamide.

Adding AR inhibitors into AI did not improve the efficacy in patients whose tumors exhibited resistance to AI. There are conflicting evidences about AR as a prognostic or predictive factor in patients with breast cancer. A study showed that AR expression was related to tumor proliferation and nuclear grade. AR negativity and ER negativity were associated with high tumor aggressiveness [19](#onco13072-bib-0019){ref-type="ref"}. Other studies showed that AR expression was associated with disease‐free survival and overall survival, regardless of subtype [5](#onco13072-bib-0005){ref-type="ref"}, [20](#onco13072-bib-0020){ref-type="ref"}, [21](#onco13072-bib-0021){ref-type="ref"}. However, the Breast International Group Trial 1‐98 study showed that AR was associated with better clinicopathological factors but not with better disease‐free survival and overall survival [22](#onco13072-bib-0022){ref-type="ref"}. Most studies targeting AR in patients with breast cancer who had disease progression after NSAI failed to prove that AR signaling was the main mechanism of AI resistance [17](#onco13072-bib-0017){ref-type="ref"}, [23](#onco13072-bib-0023){ref-type="ref"}, [24](#onco13072-bib-0024){ref-type="ref"}. AR inhibition may have value in patients with certain types of breast cancer, such as triple‐negative breast cancer [14](#onco13072-bib-0014){ref-type="ref"}, AR gene amplification [23](#onco13072-bib-0023){ref-type="ref"} or AR‐positive, ER‐positive, untreated advanced breast cancer [24](#onco13072-bib-0024){ref-type="ref"}.

It is likely that the mechanisms of AI resistance are heterogeneous in ER‐positive breast cancer, so simply blocking AR signaling may be insufficient to overcome resistance. Mutations in the PI3KCA/AKT/mTOR pathway and cell cycle regulation are more frequently detected, which could lead to more successful outcomes in overcoming AI resistance [25](#onco13072-bib-0025){ref-type="ref"}.

In terms of safety, no new adverse events were reported in our study. The frequency and clinical pattern of adverse events were consistent with the previous study [14](#onco13072-bib-0014){ref-type="ref"}.

Bicalutamide in combination with AI did not show synergistic effect in patients with ER‐positive, AR‐positive, and AI‐resistant disease. We suggest that no more large‐sample clinical trials should be conducted in this population for overcoming AI resistance.
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